Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

LY-178210

From Wikipedia, the free encyclopedia
(Redirected from C18H25N3O)

LY-178210
Clinical data
Other namesLY178210; LY-228729; LY228729; 4,α-Methylene-5-carboxamido-N,N-dipropyltryptamine; 4,α-Methylene-5-carboxamido-DPT
Drug classSerotonin 5-HT1A receptor partial agonist
ATC code
  • None
Identifiers
  • 4-(dipropylamino)-1,3,4,5-tetrahydrobenzo[cd]indole-6-carboxamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H25N3O
Molar mass299.418 g·mol−1
3D model (JSmol)
  • CCCN(CCC)C1CC2=CNC3=C2C(=C(C=C3)C(=O)N)C1
  • InChI=1S/C18H25N3O/c1-3-7-21(8-4-2)13-9-12-11-20-16-6-5-14(18(19)22)15(10-13)17(12)16/h5-6,11,13,20H,3-4,7-10H2,1-2H3,(H2,19,22)
  • Key:YTOJFUORFUYGSV-UHFFFAOYSA-N

LY-178210, also known as LY-228729 or as 4,α-methylene-5-carboxamido-DPT, is a selective and highly potent serotonin 5-HT1A receptor partial agonist.[1][2][3][4] It has an affinity (Ki) of 0.67 nM for the serotonin 5-HT1A receptor.[1][3] The drug has high selectivity for this receptor over 12 other assessed targets, including the serotonin 5-HT1D, 5-HT2A, 5-HT2C, and 5-HT3 receptors among others (Ki = ≥380–4,000 nM).[4][2][5] LY-178210 is a tricyclic simplified or partial ergoline and is structurally related to LSD.[2][1][6] It was described as a potential clinical development candidate but was not further developed and was never marketed.[5] Both LY-178210 and flesinoxan have been reported to produce anxiety in humans.[7] The drug was first reported in the scientific literature by 1990.[4]

See also

[edit]

References

[edit]
  1. 1 2 3 Glennon RA (1992). "Concepts for the design of 5-HT 1A serotonin agonists and antagonists". Drug Development Research. 26 (3): 251–274. doi:10.1002/ddr.430260306. ISSN 0272-4391. Fig. 1. Structures of some indolealkylamines: 5-HT 5-CAT (2), RU 24969 (3), (+)LSD (4), RU 28306 (5), BAY R 1531 (6), and LY 178210 (7). [...] Partial ergolines have also been examined [Flaugh et al., 1988]. For example, RU 28306 (5) binds at 5-HT1, sites with relatively low affinity (Ki = 329 nM) [Taylor et al., 1987]; however, the corresponding N,N-dipropyl-6-substituted analogs BAY R 1531 (6) [Glaser et al., 1987] and LY 178210 (7) [Slaughter et al., 1990] bind with significantly higher affinity (Ki <1 nM). These latter two agents, as with O-methyl DiPS [Glennon et al., 1988a] and N,N-dipropyl-5-carboxamidotryptamine [Hibert et al., 1987], possess 5-HT1, agonist activity. The hydroxy analog of compound 6 is apparently a full agonist [Seiler et al., 1990] whereas LY 178210 (7) acts as a partial agonist in an adenylate cyclase assay [Slaughter et al., 1990].
  2. 1 2 3 Audia JE, Cohen ML (1991). "Chapter 11. Serotonin Modulators and Cardiovascular/Gastrointestinal Diseases". Annual Reports in Medicinal Chemistry. Vol. 26. Elsevier. pp. 103–112. doi:10.1016/s0065-7743(08)61198-7. ISBN 978-0-12-040526-8. Ergolines and Partial Ergolines - Although primarily investigated as 5-HT2 receptor ligands, several ergolines, including lisuride and lysergic acid diethylamide (LSD), show high affinity for 5-HT1A receptors, although they lack selectivity (47). Some partial ergolines, including LY 178210 (8) and LY 197206 (9), show surprising selectivity as 5-HT1A agonists relative to related ergolines (65). This specificity, however, can be more readily rationalized by recognizing the similarities to the 5-HT1A-selective aminotetralins [...] From an SAR perspective, a partial ergoline such as LY 178210 (Q) does not retain this high affinity for the 5-HT1C receptor (65). [...] Miscellaneous Structures - Many ergolines, particularly metergoline and methysergide have high affinity for the 5-HT1D receptor, while other ergolines such as mesulergine and the partial ergoline LY 178210 (9) lack significant affinity at this receptor subtype (65).
  3. 1 2 Nelson DL (December 1991). "Structure-activity relationships at 5-HT1A receptors: binding profiles and intrinsic activity". Pharmacology, Biochemistry, and Behavior. 40 (4): 1041–1051. doi:10.1016/0091-3057(91)90124-k. PMID 1816558. Table 3 Effect on 5-HT1A Affinity by Substitutions at the C6 Position of a Series of Tricyclic Partial Ergolines [...]
  4. 1 2 3 Slaughter JL, Harrington MA, Peroutka SJ (1990). "6-substituted tricyclic partial ergoline compounds are selective and potent 5-hydroxytryptamine1A receptor agents". Life Sciences. 47 (15): 1331–1337. doi:10.1016/0024-3205(90)90197-y. PMID 2172684.
  5. 1 2 Perregaard J, Sánchez C, Arnt J (1993). "Overview: Recent Developments in Anxiolytics". Current Opinion on Therapeutic Patents. 3 (1): 101–128. doi:10.1517/13543776.3.1.101. ISSN 0962-2594. Many of the Lilly compounds (25) were shown to have nanomolar affinity for 5-HT1D, as well as for 5-HT1A, receptors. An exception is the clinical development candidate LY 178210, which has 500-fold less affinity for 5-HT1D receptors than for 5-HT1A receptors [88].
  6. Vangveravong S (1994). Synthesis of trans-2-(indol-3-yl)cyclopropylamines: Rigid tryptamine analogues (Ph.D. thesis). Purdue University. ProQuest 304131663. Retrieved 22 March 2025. Figure 5. Rigid Serotonin Receptor Ligands [...]
  7. Lucot JB, Brame RE, Garrett TL, Pfadenhauer EH, Kumar A, Fick DB, et al. (August 2014). "The broad-spectrum antiemetic effects ETI-385 result from stimulation of 5-HT1A and 5-HT1D receptors". Exp Brain Res. 232 (8): 2699–2707. doi:10.1007/s00221-014-4004-z. PMID 24913143. Another hindrance to the clinical evaluation of this mechanism is that both flesinoxan (van Vliet et al. 1996) and LY22879 (pers. com.) induced anxiety in humans.